Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol~* Meet all of the following criteria in at least one eye: Have more than 10 lashes with collarettes present on the upper lid; have at least mild erythema of the upper eyelid margin; have an average Demodex density, upper and lower eyelids combined, of 1.5 or more mites per lash~Exclusion Criteria:~* Have used lid hygiene products within 14 days of Screening or unwilling to forego the use of lid hygiene products during the study~* Have used a prostaglandin analogue to promote eyelash growth within 30 days of Screening or any plans to initiate treatment during the study~* Have used artificial eyelashes or eyelash extensions within 7 days of Screening or be unwilling to forego their use during the study~* Be pregnant or lactating at the time of Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
- Control (Type: PLACEBO_COMPARATOR): Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days

Based on this trial design, predict the completion outcome and termination type (if applicable).